Nitration and increased α-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction

Journal of Neuroendocrinology

Volumn 17, Issue 2, 2005, Pages 73-80

  McFarlane, Dianne ^a   Dybdal, N ^b   Donaldson, M T ^c   Miller, L ^a   Cribb, A E ^a  

^a UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

3 Nitrotyrosine; Alpha synuclein; Equine Cushing's disease; Equine pituitary pars intermedia dysfunction; Oxidative stress

Indexed keywords

3 NITROTYROSINE; ALPHA SYNUCLEIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL TISSUE; ARTICLE; BRAIN DYSFUNCTION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; GENE OVEREXPRESSION; HORSE; HORSE DISEASE; HYPOPHYSIS; HYPOPHYSIS INTERMEDIATE LOBE; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NERVE ENDING; NITRATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ALPHA-SYNUCLEIN; ANIMALS; BLOTTING, WESTERN; CHRONIC DISEASE; DOPAMINE; HORSE DISEASES; HORSES; IMMUNOHISTOCHEMISTRY; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NITROGEN; OXIDATIVE STRESS; PITUITARY ACTH HYPERSECRETION; PITUITARY GLAND; SYNUCLEINS; TYROSINE; TYROSINE 3-MONOOXYGENASE;

EID: 15844394868     PISSN: 09538194     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2005.01277.x     Document Type: Article

References (37)

1. Brosnahan MM, Paradis MR. Demographic and clinical characteristics of geriatric horses: 467 cases (1989-1999). J Am Vet Med Assoc 2003; 223: 93-98.
2. van der Kolk JH, Kalsbveek HC, van Garderen E, Wensing Th, Breukink HJ. Equine pituitary neoplasia. a clinical report of 21 cases (1990-1992). Vet Record 1993; 133: 594-597.
3. Love S. Equine Cushing's disease. Br Vet J 1993; 149: 139-153.
4. Hillyer MH, Taylor FRG, Mair TS, Murphy D, Watson TDG, Love S. Diagnosis of hyperadrenocortism in the horse. Equine Vet Educ 1992; 4: 131-134.
5. Couetil L, Paradis MR, Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. J Vet Intern Med 1996; 10: 1-6.
6. Heinrichs M, Baumgartner W, Capen CC. Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses. Vet Pathol 1990; 27: 419-425.
7. Pallaske G. Zur Kasuistik Seltnere Geschwülste bei den Haustieren. Z Krebsforschung 1932; 36: 342-353.
8. Kemppainen RJ, Zerbe CA, Sartin JL. Regulation and secretion of proopiomelanocortin peptides from isolated perfused dog pituitary pars intermedia cells. Endocrinology 1989; 124: 2208-2217.
9. Kemppainen RJ, Peterson ME. Regulation of alpha-melanocyte-stimulating hormone secretion from the pars intermedia of domestic cats. Am J Vet Res 1999; 60: 245-249.
10. Luppi PH, Sakai K, Salvert D, Berod A. Jouvet. Periventricular dopaminergic neurons terminating in the neuro-intermediate lobe of the cat hypophysis. J Comp Neurol 1986; 244: 204-212.
11. Goudreau JL, Falls WM, Lookingland KJ, Moore KE. Periventricular-hypophysial dopaminergic neurons innervate the intermediate but not the neural lobe of the rat pituitary gland. Neuroendocrinology 1995; 62: 147-154.
12. Cote TE, Eskay RL, Frey EA, Grewe CW, Munemura M, Stoof JC, Tsuruta K, Kebabian JW. Biochemical and physiological studies of the beta-adrenoceptor and the D-2 dopamine receptor in the intermediate lobe of the rat pituitary gland: a review. Neuroendocrinology 1982; 35: 217-224.
13. Orth DN, Holscher MA, Wilson MG, Nicholson WE, Plue RE, Mount CD. Equine Cushing's disease: plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests. Endocrinology 1982; 110: 1430-1441.
14. Gary KA, Chronwall BM. The onset of dopaminergic innervation during ontogeny decreases melanotrope proliferation in the intermediate lobe of the rat pituitary. Int J Dev Neurosci 1992; 10: 131-142.
15. Saiardi A, Borrelli E. Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice. Mol Endocrinol 1998; 12: 1133-1139.
16. Millington WR, Dybdal NO, Dawson R Jr, Manzini C, Mueller GP. Equine Cushing's disease. Differential regulation of β-endorphin processing in tumors of the intermediate pituitary. Endocrinology 1988; 123: 1598-1604.
17. Schott HC, Coursen CL, Eberhart SW, Nachreiner RJ, Refsal KR, Ewart SL, Marteniuk JV. The Michigan Cushing's project. Proceedings of the 47th Annual Convention of the American Association of Equine Practitioners. San Diego, CA: AAEP, 2001: 22-24.
18. Donaldson MT, LaMonte BH, Morresey P, Smith G, Beech J. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (Equine Cushing's disease). J Vet Intern Med 2002; 16: 742-746.
19. Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 2001; 40: 959-975.
20. Frank J, Pompella A, Biesalski HK. Histochemical visualization of oxidant stress. Free Radic Biol Med 2000; 29: 1096-1105.
21. Luo Y, Roth GS. The roles of dopamine oxidative stress and dopamine receptor signaling in aging and age-related neurodegeneration. Antioxid Redox Signal 2000; 2: 449-460.
22. McCormack AL, Di Monte D, Delfani K, Irwin I, DeLanney LE, Langston WJ, Janson AM. Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol 2004; 471: 387-395.
23. 3 receptor loss in extrastriatal regions of the human brain. Neurobiol Aging 2000; 21: 683-688.
24. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43: 562-571.
25. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev 1998; 78: 547-581.
26. Calabrese V, Bates TE, Stella AM. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. Neurochem Res 2000; 25: 1315-1341.
27. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
28. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-608.
29. Saha AR, Ninkina NN, Hanger DP, Anderton BH, Davies AM, Buchman VL. Induction of neuronal death by alpha-synuclein. Eur J Neurosci 2000; 12: 3073-3077.
30. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Bjorklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 2002; 22: 2780-2791.
31. Lauwers E, Debyser Z, Van Dorpe J, De Strooper B, Nuttin B, Baekelandt V. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol 2003; 13: 364-372.
32. Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet 2001; 10: 3101-3109.
33. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
34. Holzmann C, Kruger R, Saecker AM, Schmitt I, Schols L, Berger K, Riess O. Polymorphisms of the alpha-synuclein promoter: expression analyses and association studies in Parkinson's disease. J Neural Transm 2003; 110: 67-76.
35. Farrer M, Maraganore DM, Lockhart P, Singleton A, Lesnick TG, de Andrade M, West A, de Silva R, Hardy J, Hernandez D. Alpha-synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 2001; 10: 1847-1851.
36. Tan EK, Tan C, Shen H, Chai A, Lum SY, Teoh ML, Yih Y, Wong MC, Zhao Y. Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. Neurosci Lett 2003; 336: 70-72.
37. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000; 290: 985-989.